Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Nivolumab and Vorolanib in Treating Patients with Non-Small Cell Lung Cancer and Refractory Thoracic Tumors

Multiple Cancer Types

This phase I / II trial studies the side effects and best dose of vorolanib when given in combination with nivolumab in treating patients with non-small cell lung cancer and thoracic tumors that aren't responding to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vorolanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and vorolanib may work better in treating patients with non-small cell lung cancer and thoracic tumors.
Lung, Non Small Cell
I/II
Horn, Leora
NCT03583086
VICCTHO1802

Testing Treatment with Ipilimumab and Nivolumab Compared to Treatment with Ipilimumab Alone in Advanced Melanoma

Melanoma

This phase II trial studies how well ipilimumab with or without nivolumab work in treating patients with melanoma that is stage IV or stage III and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Melanoma
II
Johnson, Douglas
NCT03033576
ECOGMELS1616

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: